Abstract
clinical research: issues for clinical investigators. Acad Med. 2003;78:769-774. 37. Mirowski P, Van Horn R. The contract research organization and the commercialization of scientific research. Social Studies of Science. 2005;35:503-548. 38. American Medical Student Association. Principles regarding pharmaceuticals and medical devices. Available at: http://www. amsa.org/about/ppp/pharm.cfm. Accessed April 1, 2007. 39. Coleman DL, Kazdin AE, Miller LA, et al. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school’s approach. Academic Medicine. 2006;81:154-160. 40. Grady MS, Kennedy DW. Guidelines for interactions between healthcare professionals and industry. Hospital of the University of Pennsylvania /Clinical Practices of the University of Pennsylvania Clinical Practice Guideline, Sept. 27, 2006 Available at: http://www. uphs.upenn.edu/cep/resources/PhARMA%202-202006%20profindustry.pdf. Accessed April 1, 2007. 41. Pharmaceutical company representative activity. HUP/CPUP Policy Manual, Sept. 27, 2006. Available at: http://www.uphs.upenn. edu/cep/resources/1_12_41%20pharma%20policy.pdf. Accessed April 1, 2007. 42. Duke University Health System. Pharmaceutical and nutritional vendors: policy and procedures and FAQs. 2003; revised 2005. Available at: http://pharmacy.mc.duke.edu/PT/. Accessed April 1, 2007. 43. Ross JS, Lackner JE, Lurie P, et al. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007; 297: 1216-1223. 44. Stark A. Conflict of Interest in American Public Life. Cambridge: Harvard, 2000.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call